Regeneron Pharmaceuticals, Inc. - Common Stock (REGN) is currently showing a slightly bullish headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: There is a mild positive lean in the higher-value headlines, though the setup is not strong enough to call decisively bullish.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor.com
NEWS SCORE
65/100
Slightly Bullish
Bearish
Neutral
Bullish
Earnings Tone
78
Good based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$664.45
Trend Context
Mixed / range
Latest briefing
What's happening with REGN
247wallst.com7 Jul 2026
Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”
On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
fool.com1 Jul 2026
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
It might pull it off, provided several things fall right in place.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
reuters.com29 Jun 2026
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
The U.S. Food and Drug Administration has selected Eli Lilly and Regeneron , among seven companies, for a pilot program to accelerate reviews of new domestic pharmaceutical manufacturing facilities, CNBC reported on Monday citing an FDA spokesperson.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
fool.com
27 Jun 2026
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
